Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
Hims & Hers Health Stock Is Rising Monday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...
Is Hims & Hers rally at risk as GLP-1 shortages ease?
Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Fast Company6d
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...